1. Myelosuppression: Reversible myelosuppression is the most serious adverse reaction of this drug. This response is related to the dosage and course of treatment. It is common in patients whose blood concentration exceeds 25 μg / ml. Clinical manifestations are anemia, and can be associated with leukocytes and thrombocytopenia.
2. Aplastic anemia
: Aplastic anemia is rare after medication. Its clinical manifestations include bleeding tendency due to thrombocytopenia, concurrent stasis, ecchymosis, and nosebleeds, as well as signs of infection caused by granulocytopenia, such as fever, sore throat, and jaundice.
3. Gray infant syndrome: There have been no reports of "gray infant syndrome" caused by the use of this drug in preterm infants and newborns.
4. Hepatotoxicity: People with existing liver disease may cause jaundice, liver fat infiltration, and even acute severe hepatitis.
5. Allergic reactions: Allergic reactions such as rash, solar dermatitis, angioedema, and drug fever are rare after taking the drug, and the general symptoms are mild.
6. Nervous system: Peripheral neuritis and optic neuritis can occur after long-term medication, manifested as neurological symptoms such as hearing loss, insomnia, hallucinations, delirium, etc., which are mostly reversible. Optic nerve atrophy and blindness have also been reported after long-term use.
7. Gastrointestinal reactions: Gastrointestinal symptoms such as loss of appetite, nausea, vomiting, epigastric discomfort, and diarrhea are more common after administration, and the incidence is less than 10%.
8. Double infection: After long-term use, the normal flora in the body can be reduced, causing double infection.
9. Others: (1) Some patients with congenital glucose-6-phosphate dehydrogenase deficiency may develop hemolytic anemia after administration; (2) Long-term oral administration may inhibit the intestinal flora and block vitamin K synthesis. Induces bleeding tendency.